Connection

M ATASSI to Botulinum Toxins

This is a "connection" page, showing publications M ATASSI has written about Botulinum Toxins.
Connection Strength

3.853
  1. Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions. Toxicon. 2015 Dec 01; 107(Pt A):50-8.
    View in: PubMed
    Score: 0.420
  2. Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other. Protein J. 2014 Jun; 33(3):278-88.
    View in: PubMed
    Score: 0.391
  3. Location of the synaptosome-binding regions on botulinum neurotoxin B. Biochemistry. 2012 Jan 10; 51(1):316-28.
    View in: PubMed
    Score: 0.330
  4. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.327
  5. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
    View in: PubMed
    Score: 0.323
  6. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol. 2010; 30(2):167-87.
    View in: PubMed
    Score: 0.288
  7. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action. Toxicon. 2009 Oct; 54(5):600-13.
    View in: PubMed
    Score: 0.272
  8. The binding sites on botulinum neurotoxin B for synaptotagmin and for blocking antibodies. Biochem Biophys Res Commun. 2008 Nov 21; 376(3):631-2.
    View in: PubMed
    Score: 0.263
  9. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
    View in: PubMed
    Score: 0.261
  10. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol Immunol. 2008 Feb; 45(4):910-24.
    View in: PubMed
    Score: 0.246
  11. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.233
  12. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004 Mar; 19 Suppl 8:S68-84.
    View in: PubMed
    Score: 0.192
  13. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
    View in: PubMed
    Score: 0.172
  14. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol. 1999; 19(3):219-60.
    View in: PubMed
    Score: 0.134
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.